David A. Berry
Independent DirectorDr. David A. Berry, Ph.D., M.D., serves as Managing Partner at Averin Capital, LLC. He also serves as Chairman and Chief Executive Officer of Averin Capital Acquisition Corp. from October 21, 2025. Dr. Berry is Chairman of Oxford Impedance Diagnostics Limited from 2023, Independent Director of Oaktree Acquisition Corp. III Life Sciences from October 17, 2025, Director of Biolinq Incorporated, Director of Boston Philharmonic, and Co-Owner of Handel Rose Llc. He is Founder of Ohana Biosciences, Inc. Additionally, he serves as Chairman of Osler Diagnostics Limited, Director of Hologen Inc., Director of Mari Agriculture, Board Observer at Salma Health, Inc., and serves on the Leadership Council of the United Nations Sustainable Development Solutions Network. Dr. Berry was a General Partner at Flagship Pioneering, Inc. from 2008 to February 2024. At the firm, he also served as Partner, which he joined in 2005. He is Founder of Valo Health, Inc. and also served as President, Chief Executive Officer, and Director from 2018 until January 16, 2024. He is Founder of Omega Therapeutics, Inc. and also served as an Independent Director from August 2017 to June 8, 2022. He served as an Independent Director at Axcella Health Inc., where he was employed from 2009 until May 2020. He was a Trustee of Hackley School Inc. from July 2010 to 2019. He served as a Director of Evelo Biosciences, Inc. from 2015 to 2018. He is Co-Founder of Evelo Therapeutics, Inc. He was Founding Chief Executive Officer of Senda Biosciences, inc. from July 2017 to 2018 and also served as a Director. He served as a Director at Sesen Bio, Inc., where he was employed from August 2009 to August 15, 2016. He served as a Director of Eleven Biotherapeutics, Inc. from August 2009 to August 15, 2016. He served as a Director of Seres Therapeutics, Inc. from 2010 to 2015. He is Co-Founder of Seres Therapeutics, Inc. and was employed at the company from September 2010 to May 30, 2014. He served as a Director of Avedro, Inc. from August 2013 to May 2015. He is Co-Founder of Seres Health, Inc. and also served as its Chief Executive Officer from March 29, 2013 to May 30, 2014. He served as a Director of Boston Philharmonic Orchestra from September 2010 to July 2014. He is Co-Founder of Joule Unlimited, Inc., where he was involved from 2007 to 2014, and also served as Chief Executive Officer and President until April 2009. He also served as a Director of Joule Unlimited. He is Co-Founder of Pronutria and also served as its Chief Scientific Officer. He also served as Chief Executive Officer and President at Pronutria until March 2012. He was a Member of the Board of Trustees at MIT Corporation from 2006 to 2011. He served as a Director of CGI Pharmaceuticals, Inc. from September 2009 to July 2010. He is Co-Founder of Theracrine, Inc., which he joined in 2010, and also served as Chairman and Chief Executive Officer. He also served as a Director of Theracrine. He is Co-Founder of LS9, Inc., which he co-founded in November 2005. He is a Co-Founder at Eleven Biotherapeutics, Inc. and Symbiota, where he served as the founding Chief Executive Officer. He also served as a Director of Symbiota. His prior roles include Principal of Flagship Ventures and Director of Tarveda Therapeutics, Inc., Blend Therapeutics, Inc., and Indigo Inc. He is Co-Founder and also served as Director of Indigo Ag, Inc. He was a Director of Juventas New Music Ensemble. Dr. Berry focuses on AI, Healthcare, Early Stage, Life Science, Susutainability, and Cleantech. His work has led to the founding of approximately 30 companies and has served as CEO of more than 10. His work has led to numerous peer-reviewed publications and more than 200 patents and applications. He was elected a 2014 Young Global Leader by the World Economic Forum, recognized in the 2013 PharmaVOICE 100, and was a 2012 Boston Business Journal 40 under 40 honoree. He was named Innovator of the Year by MIT Technology Review in its 2007 TR35 list, selected by the US State Department as one of a select group of Innovators Helping to Reshape Realty, and won the Lemelson-MIT Student Prize in 2005. He has been recognized multiple times by Biofuels Digest as one of the “Top 100 People in Bioenergy” and was named a Member of the Global Board for the MIT Enterprise Forum in 2010. Dr. Berry received an M.D. from Harvard Medical School from 2000 to 2006 and a Ph.D. in Biological Engineering from Massachusetts Institute of Technology from 2002 to 2005, completing the dual degree through the Harvard-MIT Health Sciences and Technology program. He holds a B.S. in Brain Science & Cognitive Sciences, Phi Beta Kappa and Sigma Xi, from Massachusetts Institute of Technology from 1996 to 2000. He graduated from Hackley School in 1996.
Positions
- Company NameOaktree Acquisition Corp. III Life SciencesStock CodeOACCPositionIndependent DirectorRelated Securities
- Company NameAverin Capital Acquisition Corp.Stock CodeACAAPositionChairman & CEORelated Securities
